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Prognostic Relevance of CCDC88C 
(Daple) Transcripts in the Peripheral 
Blood of Patients with Cutaneous 
Melanoma
Ying Dunkel1, Anna L. Reid2, Jason Ear  1, Nicolas Aznar  1,3, Michael Millward4,5, Elin Gray  2, 
Robert Pearce2, Melanie Ziman  2,6 & Pradipta Ghosh1,7,8
A loss of balance between G protein activation and deactivation has been implicated in the initiation 
of melanomas, and non-canonical Wnt signaling via the Wnt5A/Frizzled (FZD) pathway has been 
shown to be critical for the switch to an invasive phenotype. Daple [CCDC88C], a cytosolic guanine 
nucleotide exchange modulator (GEM) which enhances non-canonical Wnt5A/FZD signaling via 
activation of trimeric G protein, Gαi, has been shown to serve opposing roles–as an inducer of EMT and 
invasiveness and a potent tumor suppressor–via two isoforms, V1 (full-length) and V2 (short spliced 
isoform), respectively. Here we report that the relative abundance of these isoforms in the peripheral 
circulation, presumably largely from circulating tumor cells (CTCs), is a prognostic marker of cutaneous 
melanomas. Expression of V1 is increased in both the early and late clinical stages (p < 0.001, p = 0.002, 
respectively); V2 is decreased exclusively in the late clinical stage (p = 0.003). The two isoforms have 
opposing prognostic effects: high expression of V2 increases relapse-free survival (RFS; p = 0.014), 
whereas high expression of V1 tends to decrease RFS (p = 0.051). Furthermore, these effects are 
additive, in that melanoma patients with a low V2-high V1 signature carry the highest risk of metastatic 
disease. We conclude that detection of Daple transcripts in the peripheral blood (i.e., liquid biopsies) of 
patients with melanoma may serve as a prognostic marker and an effective strategy for non-invasive 
long-term follow-up of patients with melanoma.
Melanoma is a highly malignant cancer and causes more deaths than other forms of skin cancer; as in most 
cancers, early detection and surgical intervention are imperative for a curative outcome. However, in the case of 
melanoma, even with ‘curative’ surgical resection, the risk of recurrence is never completely absentand late recur-
rences, even beyond 8 years (y), can occur at a frequency ranging from 0.41% to 25% across different studies, with 
6.8% at 15 y and 11.3% at 25 y1,2. The late recurrence population is particularly interesting to study as it represents 
a group of patients exhibiting tumor dormancy, defined as a stage in cancer progression in which residual disease 
is present but remains asymptomatic2. Hence, early detection of patients in this clinical stage of melanoma is of 
paramount importance so that they can be offered adjuvant therapy.
Tumor dormancy is best studied by examining patients who demonstrate persistent circulating or dissemi-
nated tumor cells (CTC or DTC) after removal of all clinically evident disease3. In fact, metastatic melanoma was 
the first malignancy in which CTCs were detected4. More recently, the presence of circulating melanoma cells 
(CMCs) in the peripheral blood of patients with metastatic cutaneous melanoma has been identified by detecting 
mRNA transcripts of specific melanoma markers. These specific transcripts from one or more CMCs in 10 ml of 
peripheral blood can be identified in 45% of all melanoma patients at varying disease stages (AJCC Stages I/II, 
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III, and IV: 35%, 44%, and 86%, respectively)5–9. While the prognostic impact of the number of CMCs remains to 
be determined, the prognostic impact of detecting molecular markers from these CMCs in the peripheral blood 
of melanoma patients has been evaluated by multiple groups within the last decade. These studies are in general 
agreement that the detection of unique multi-panel biomarkers such as S100B, MAGE-3, p97, MUC-18, S100A4, 
MART1, HMB45, and tyrosinase, by real-time quantitative PCR (qRT-PCR) in CMCs of melanoma patients can 
have a valuable prognostic utility, especially in patients with Stage II and III disease10–14. These studies demon-
strate that molecular detection of CMCs may be valuable to detect early disease recurrence and to stratify patients 
for adjuvant therapy. However, given the heterogeneous nature of melanoma cells, no single marker or panel of 
markers appears to be sufficiently robust in predicting outcome.
Despite these insights, the identification of CMC-biomarkers with strong rationale and mechanistic insights 
and within specific signaling pathways known to fuel melanoma metastasis,remains unexplored and unrealized. 
In this regard, several studies agree that activation of non-canonical Wnt signaling and inactivation of the canon-
ical Wnt pathway is associated with metastatic features of melanoma and thus poor survival15–17. Here we report 
the identification of Daple (CCDC88C), a cytoplasmic transducer of Wnt signals18–20, as a candidate marker 
for monitoring deregulated Wnt signaling during melanoma progression. Daple links ligand-activated Frizzled 
receptors to Gi protein activation18. Such activation, on one hand antagonizes the canonical Wnt pathway and 
suppresses a neoplastic transformation and tumor growth. On the other hand, it enhances non-canonical Wnt 
pathway and Akt signals, triggering epithelial-mesenchymal transition (EMT) and tumor invasion18. Subsequent 
work unraveled that Daple-dependent modulation of Wnt signaling is triggered not just by Wnt ligands18, but also 
by growth factors (EGF)20 and junctions-associated Cadherin-catenin complexes that trigger the PI3K-Akt path-
way19. Perhaps as a consequence of such convergent signaling, ourselves and others have demonstrated Daple’s 
role in fueling the metastatic progression of gastric21 and colorectal cancers (CRCs)18,22 and its ability to serve as 
a prognostic marker in the CTCs of patients with metastatic CRCs22,23. We hypothesized that detection of Daple 
transcripts in the peripheral blood of patients with melanoma may serve as a surrogate marker for deregulated 
Wnt signaling during melanoma progression. Our findings present evidence that tracking levels of its transcripts 
could serve as an effective strategy for non-invasive long-term follow-up of patients with melanoma.
Results and Discussion
Rationale for choosing Daple as a biomarker for metastatic progression of melanoma. We pre-
viously reported that the Disheveled-binding protein, Daple, is a guanine nucleotide exchange modulator (GEM) 
for heterotrimeric G proteins within the Wnt signaling cascade18. Subsequent work revealed that the human 
Daple/CCDC88C gene is expressed as two functional isoforms: Daple-full length (V1) (2028aa) and Daple-V2 
(552aa)22. These isoforms serve contrasting roles during cancer progression; while both isoforms cooperatively 
antagonize Wnt signaling and suppress tumor cell proliferation and growth via their G protein binding and acti-
vation (GBA) motif18, only the full-length V1 isoform triggers EMT and invasion. In the colon, both isoforms 
collaboratively suppress tumor cell growth, and have an additive prognostic impact (worse outcome when both 
are suppressed). However, only Daple-V1 is increased in invasive tumor margins and in CTCs disseminated 
during CRC progression. We next chose to study the role of Daple in melanoma, which, like colorectal cancers, is 
another cancer that is characterized by dysregulation of heterotrimeric G-protein as well as Wnt signaling; prior 
studies have implicated both pathways in the metastatic progression of melanomas24,25. When we analyzed the 
RNA sequencing dataset from The Cancer Genome Atlas (TCGA) for dysregulation of Daple/CCDC88C expres-
sion (CNVs, deletions or mutations) and the frequently mutated heterotrimeric G-protein GNAQ26, we found 
that mutations have been identified in patients with cutaneous, but not uveal melanomas for Daple/CCDC88C. 
For GNAQ, on the other hand, although mutations have been identified in both cutaneous and uveal melanomas, 
these are predominantly found in uveal melanomas (Fig. 1A,B). Mutations found in Daple/CCDC88C included 
both missense and truncating mutations (Supplemental Figs S1 and S2). Notably, mutations in other heterotri-
meric G-protein α-subunits (GNAI1, GNAI2, GNAI3, and GNAS) that are modulated by this family of GEMs 
(of which Daple is a member and CCDC88A/Girdin and NUCB1/2 are others27) were only found in cutaneous 
melanomas (Fig. 1B). These findings, along with the observation that Daple/CCDC88C was indeed abundantly 
expressed in distant metastases to diverse organs or sites (Supplemental Fig. S3), led us to hypothesize that dysreg-
ulated signaling via Daple/CCDC88C in cutaneous melanomas may have a role in the progression to metastatic 
disease. If so, that would imply that deregulated G protein signaling may be a common theme in both cutaneous 
and uveal melanomas–In uveal melanomas such deregulation is directly mediated by oncogenic mutations in the 
G protein α-subunit (GNAQ), whereas in cutaneous melanomas such deregulation may be indirectly mediated 
via mutations and altered expression of modulators of G proteins such as Daple-GEM.
Transcripts of Daple-V1 (V1), but not Daple-V2, is increased in the peripheral circulation of 
patients with melanoma. We recently showed that the expression of Daple full-length (Daple-V1) was 
elevated in EpCAM-immuno-isolated CTCs of colorectal cancer patients, and that Daple promotes EMT during 
tumor cell dissemination and disease progression18,22. Expression of Daple-V2, on the other hand, was found 
to be decreased in primary CRC tumors22. Because Daple-V1 and -V2 are differentially expressed in CTCs of 
CRCs patients, we first asked if this is also the case in patients with melanoma (see Table 1 for patient cohort 
characteristics). Because detection of gene transcripts in the peripheral blood is a sensitive surrogate marker of 
melanoma CTCs8,28, we analyzed the abundance of Daple transcripts in the peripheral blood of patients with 
melanoma (n = 205)and of healthy controls (n = 142) by qRT-PCR. We found that patients with melanoma have 
significantly elevated level of Daple-V1 expression compared to normal healthy controls (p < 0.0001; Fig. 2). The 
same pattern of expression was observed as for the melanocyte marker and the metastasis-associated protein, 
S100A429, which is a transcriptional target of the Wnt/β-Catenin pathway30 and currently used as a marker to 
diagnose melanoma31. By contrast, no difference in Daple-V2 expression was observed between transcripts in 
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peripheral blood of melanoma patients and the healthy controls (Fig. 2). These findings indicate that transcripts 
of full length Daple-V1, but not V2 are selectively upregulated in patients with melanoma and suggest that high 
levels of Daple-V1 may contribute to melanoma progression.
Transcripts of Daple-V1 increase, but Daple-V2 decrease in the peripheral blood of patients 
during melanoma progression. To further dissect the patterns of expression of Daple-V1 and Daple-V2 
relative to disease stage, we analyzed both isoforms in the peripheral circulation of patients with early stage (AJCC 
stages 0, I, II) vs. late stage (AJCC stages III, IV) melanomas. We found that Daple-V1 expression is significantly 
increased in both early (p < 0.001; Fig. 3A) and late (p = 0.002; Fig. 3A) stages compared to healthy controls. 
Expression of Daple-V2 is significantly lower in late stage melanoma compared to early stage disease and healthy 
controls (p = 0.008 and 0.003, respectively; Fig. 3B); no significant differences were noted between healthy and 
early stage melanoma patients. Levels of S100A4 expression, the positive control we used in this study, were 
increased in both early (0, I, II) and late (III, IV) stages (Fig. 3C) compared to normal healthy controls (p < 0.001 
and 0.01, respectively). The changes in Daple expression we observe relative to disease stage are consistent with 
the patterns of Daple-V1 vs. V2 expressionin CRC stages; in both scenarios Daple-V1 increases but Daple-V2 
decreases as the disease progresses from the early state to the late invasive stage and undergoes hematogenous dis-
semination. The change in these transcripts in peripheral blood may reflect the entrance of CTCs into the periph-
eral circulation22. We separated the patients with high expression of Daple-V1/V2 and low expression group in 
each clinical stage (stages 0, I, II, III, IV) based on the quantitative mRNA estimation by qPCR and looked for an 
association between clinical stage of melanoma and the level of expression of Daple-V1/V2. We found that only 
Daple-V2 levels significantly change with increasing clinical stage (p = 0.0354; Fig. 4A), which is consistent with 
the correlation analysis shown in Supplemental Table 3. This finding further suggests that Daple-V2 may play an 
important role during melanoma progression.
Elevated Daple-V1 and suppressed Daple-V2 transcripts in the peripheral circulation of patients 
with early stage melanoma carries an increased risk for distant metastasis. Next, we asked if 
the levels of expression of Daple-V1 and Daple-V2 in the peripheral blood of early stage melanoma patients 
can correlate with the frequency of progression tometastatic disease. In 145 patients with early stage melanoma, 
who progressed to metastatic disease later, we found that low expression of Daple-V2 was associated with a 
Figure 1. Daple expression is altered (deleted or mutated) in cutaneous, but not in uveal melanomas. (A) 
Graphs display the levels of expression of CCDC88C/Daple (left) and GNAQ (right) in cutaneous melanoma vs. 
uveal melanoma patients in The Cancer Genome Atlas (TCGA) dataset. Individual point represents mutational 
status of each patient. While CCDC88C mutations are restricted to cutaneous melanomas, GNAQ mutations 
are found predominantly in uveal melanomas. (B) Frequency of gene alterations in cutaneous melanoma 
vs. uveal melanoma patients in The Cancer Genome Atlas (TCGA) dataset is shown for CCDC88C (Daple) 
and heterotrimeric G-proteins (GNAI1, GNAI2, GNAI3, GNAS, and GNAQ). Mutations in CCDC88C and 
GNAI and GNAS proteins were observed exclusively in cutaneous melanomas. Mutations in GNAQ was 
predominantly observed in uveal melanomas.
www.nature.com/scientificreports/
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higher metastatic rate (14.44%) compared to high expression of Daple-V2 (1.82%; p = 0.0174; Fig. 5A). This 
pattern was not seen in the case of Daple-V1; in fact, high expression of Daple-V1 tracked with higher metastatic 
rate (16.33%) compared to low expression of Daple-V1, although that trend did not reach significance (6.25%; 
Prognostic factor
Number of 
patients
Sex
Male 128
Female 77
AJCC stage
0 37
I 71
II 37
III 25
IV 35
Primary site
Face 35
Neck 4
Torso 48
Arms 43
Legs 35
Scalp 12
Unknown 28
Breslow thickness 
(mm)
<1 mm 92
1–4 mm 66
>4 mm 24
Unknown 23
Clark level
I 40
II 26
III 26
IV 76
V 12
Unknown 25
Ulceration
No 163
Yes 26
Unknown 16
Table 1. Characteristics of patient cohort analyzed in this study.
Figure 2. Comparison of the expression of Daple (isoforms V1 and V2) and S100A4 in the peripheral blood 
of patients with cutaneous melanoma vs. normal healthy subjects. Expression of Daple V1, V2 and S100A4 
(positive control) mRNA were analyzed by qPCR in patients with melanoma (n = 205) and in normal 
healthy controls (n = 142). Findings are displayed as box plots for the relative mRNA expression of each gene 
normalized to GAPDH using standard curve method. The statistical significance of the difference for each gene 
between melanoma group and normal group was calculated by t-test. Levels of expression were significantly 
elevated for Daple-V1 and S100A4 (positive control), but not Daple-V2 in patients with melanoma compared to 
healthy normal subjects.
www.nature.com/scientificreports/
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Figure 3. The expression of Daple isoforms V1 (A) and V2 (B) and S100A4 (C) in the peripheral blood of 
normal subjects and of patients with early or late-stage melanomas. Expression of Daple V1, V2 and S100A4 
(positive control) mRNA were analyzed in patients with early (clinical stage 0, I, and II; n = 145) or late (clinical 
stage III and IV; n = 60) stage melanoma and in normal healthy controls (n = 142) by qPCR. Findings are 
displayed as box plots for the relative mRNA expression of each gene normalized to GAPDH as in Fig. 2. The 
statistical significance of the difference for each gene between groups with either early or late-stage melanoma 
and normal healthy controls was calculated by t-test. While transcripts of Daple-V1 (A) and S100A4 (C) are 
elevated in both early and late stage melanomas, those of Daple-V2 are reduced exclusively in late stages of 
melanoma.
Figure 4. The association between the clinical stage of melanoma and the levels of expression of Daple isoforms 
V1 (A) and V2 (B) and S100A4 (C) in the peripheral blood. Expression level of Daple V1, V2 and S100A4 
(positive control) mRNA were analyzed in patients with different stage (clinical stage 0, I, II, III, IV) melanoma 
by qPCR. Findings are displayed as bar graphs showing the proportion of patients (Y axis) in each stage with 
low vs. high expression of indicated genes. The statistical significance of the associations between stages and the 
expression levels of Daple-V1, V2 and S100A4 were calculated by Chi-square test for trend. The optimal cut-off 
values for high vs low gene expression levels were derived by maximally selected log-rank statistics performed 
using Cutoff Finder (R Software v2.15.0) (see Table 4).
www.nature.com/scientificreports/
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p = 0.073; Fig. 5B). When we compared the rates of metastatic progression among various groups with high 
vs. low Daple-V1 and/or V2, we found that the group with the signature of low Daple-V2 and high Daple-V1 
progresses to metastasis more frequently (36.36%) compared to all other groups (Fig. 5C). These findings sug-
gest that an analysis that accounts for the levels of expression of both Daple isoforms could perform better in 
Figure 5. Frequency of progression to metastasis among patients stratified based on high vs. low levels of 
circulating transcripts of Daple-V2 alone (A), Daple-V1 alone (B), Daple V1 and V2 combined (C), and S100A4 
(D) in the peripheral blood. Bar graphs display the proportion of patients who progressed to metastasis (Y axis) 
in patients with low vs. high expression of indicated genes. Fisher exact test was used to compare each subgroup. 
(A) Compared to those with high Daple-V2 expression (n = 55), those with low Daple-V2 (n = 90) expression 
displayed higher frequency of metastatic progression. (B) Compared to those with low Daple-V1 expression 
(n = 96), those with high Daple-V1 (n = 49) expression displayed higher frequency of metastatic progression. 
(C) Compared to those with low-V1-low-V2 (n = 68), high-V1-high-V2 (n = 27) and low-V1-high-V2 
(n = 28) signatures, those with high-V1-low-V2 (n = 22) expression displayed higher frequency of metastatic 
progression. (D) Compared to those with low S100A4 expression (n = 63), those with high S100A4 (n = 82) 
expression displayed higher frequency of metastatic progression.
Univariates p-value
Hazard Ratio 
[HR]
95% confidence 
interval [CI]
Low Daple-V2 0.0403 8.4006 1.0988 to 64.2249
High Daple-V1 0.1116 2.3987 0.8164 to 7.0472
Low Daple-V2 + High Daple-V1 0.0325 9.8416 1.2100 to 80.0448
Table 2. Univariate analysis.
www.nature.com/scientificreports/
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prognosticating outcome than each one alone, i.e., Daple-V1 and Daple-V2 may have anadditive prognostic 
impact. The high expression of the metastasis-associated protein, S100A429 was also somewhat indicative of a 
higher metastatic rate among the high expressing group (13.41%) compared to the low expressing group (4.76%; 
p = 0.095; Fig. 5D) but did not reach significance. We speculate that the prometastatic trends we observed in 
the case of both Daple-V1 and S100A4 did not reach significance because of insufficient patients in the cohort. 
Regardless, these findings are consistent with our recent findings that Daple-V2 is a potent tumor suppressor, 
whereas Daple-V1 triggers EMT and invasion18,22.
Finally, we also found that patients with low Daple-V2 transcripts in their peripheral circulation had higher 
levels of other melanoma cell markers (Fig. S4A,B; Supplementary Table S4; data from7), indicating that these 
patients may have higher numbers of circulating melanoma cells. Compared to patients with high Daple-V2, 
those with low Daple-V2 had a higher incidence of detectable ABCB5 (Fig. S4B), a melanoma stem cell marker; 
no relationships were observed with Daple-V1. Taken together, these findings suggest that Daple-V2 alone may 
serve as an effective prognostic marker in early stage melanoma.
Prognostic impact of Daple-V1 and Daple-V2 in patients with melanoma. Because the frequency 
of metastatic progression was different for patients with high vs. low expression of transcripts for Daple-V1 or -V2 
in the peripheral circulation at an early stage of disease (stage 0, I, II), we asked if levels of these transcripts can 
prognosticate relapse-free survival (RFS). Kaplan-Meier curves for high vs. low levels of expression of Daple-V1 
and -V2 were plotted and compared between the two groups using the log rank test. In the case of Daple-V2, we 
found that RFS for patients with low expression was significantly reduced compared to patients with high expres-
sion (p = 0.014; Fig. 6A). While in the case of Daple-V1, we found that patients with high expression tend to have 
shorter RFS compared to patients with low expression (p = 0.051; Fig. 6B). A similar pattern was found in RFS 
analysis of S100A4; patients with high expression tend to have shorter RFS compared to patients with low expres-
sion (p = 0.083; Fig. 6C), but in both cases did not reach significance. These results indicate that Daple-V2, but not 
V1is a favorable prognostic indicator of RFS. Next we asked if the prognostic impact of Daple-V1 and Daple-V2 
are additive. When we compared RFS between the group with low Daple-V1/high Daple-V2 and the group with 
high Daple-V1-low Daple-V2, we found that patients with low Daple-V1/high Daple-V2 have a much higher RFS 
than the other group (p = 0.013; Fig. 6D), indicating that Daple-V1 improves the prognostic value of Daple-V2.
Stratification of patients by accounting for the expression levels of both Daple-V1 and 
Daple-V2 offers novel prognostic signatures. To identify the most effective diagnostic algorithm that 
combines the prognostic impacts of both Daple isoforms, we explored if assessment of Daple-V1 among the 
patients with low Daple-V2 can improve the prognostic impact of Daple-V2. When we stratified patients with 
Figure 6. Association of relapse-free survival (RFS) with expression level of Daple isoforms V2 and V1 (A,B,D) 
and S100A4 (C). Kaplan-Meier plots for RFS (% survival; y-axis) of 145 patients with early stage melanoma 
was stratified based on levels of Daple-V2 alone (A) Daple-V1 alone (B) S100A4 alone (C) and Daple-V1 + V2 
combined (D) and plotted against duration of follow-up (days to progression; x-axis). Although high Daple-V2, 
low Daple-V1 and low S100A4 carried better prognosis, statistical significance was reached only for Daple-V2. 
The positive prognostic impact of Daple-V2 and the negative prognostic impact of Daple-V1 were additive (D).
www.nature.com/scientificreports/
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low Daple-V2 into two groups with high and low Daple-V1, we found that patients with high expression of 
Daple-V1 have shorter RFS than those with low expression of Daple-V1 (p = 0.001; Fig. 7A). RFS among patients 
with low Daple-V2-high Daple-V1 expression was significantly lower than those with high Daple-V2 expression 
(p < 0.0001; Fig. 7B).
We further evaluated the effect of Daple-V1 and -V2 on survival rates by univariate and multivariate analyses 
after adjustment for clinical covariates including age and tumor stage using Cox proportional hazard regression 
model (Cox analyses; Tables 2 and 3). We found that Daple-V2 can be an independent prognostic factor; RFS of 
patients with low Daple-V2 expression was significantly lower than those with high Daple-V2 (hazard ratio [HR] 
8.4006; p = 0.0403; 95% confidence interval [CI]1 1.0988 to 64.2249) in univariate analysis and hazard ratio [HR] 
8.8907; p = 0.0366; 95% confidence interval [CI] 1.1462 to 68.9638 in multuvariate analysis). Univariate analy-
ses also confirmed that Daple-V1 and Daple-V2 have additive prognostic value; RFS was significantly reduced 
when patients have high Daple-V1 and low Daple-V2 (HR 9.8416; p = 0.0325; confidence interval [CI] 1.2100 
to 80.0448). However, multivariate analysis didn’t show the additive prognostic value of Daple-V1 and V2. The 
reason could be that the expression levels of Daple-V1 and V2 are not associated with age and the expression level 
of Daple-V1 is not associated with stages. Thus when taken together these unassociated variables for analysis, the 
power of a single variable is weakened. Although statistical significance was reached in each case, it is noteworthy 
that the 95% CIs are wide and further studies with larger cohort sizes are warranted. Regardless, both log-rank 
and Cox analyses are in agreement that Daple-V2 alone is a sufficient prognostic factor, and that risk stratification 
for tumor progression improves by the additive effect of Daple-V1 and Daple-V2. Risk was lowest when patients 
have low Daple-V1-high Daple-V2 signature, and higher when patients have a high Daple-V1-low Daple-V2 
signature.
Conclusions
The most important discovery we report here is a unique Daple/CCDC88C transcript signature, ‘high Daple-V1 
and low Daple-V2’ in the peripheral blood of patients with early stage cutaneous melanoma that effectively strat-
ifies patients at the highest risk for progression to metastatic disease. Daple-V1 triggers EMT via enhancement of 
non-canonical (β-catenin-independent) Wnt signals and suppresses canonical (β-catenin-dependent) Wnt sig-
nals18, whereas Daple-V2 serves primarily as a potent tumor suppressor22. Therefore, an increase in Daple-V1 at 
Figure 7. Stratification of patients with low Daple-V2 based on their levels of expression of Daple V1 further 
improves the prognostic power of Daple-V2. (A) Kaplan-Meier plots for RFS (% survival; y-axis) of 90 patients 
with early stage melanoma with low levels of Daple-V2 expression was stratified based on levels of expression of 
Daple-V1. (B) An overlay of Kaplan-Meier plots displayed in Fig. 6A [i.e., RFS among patients stratified based 
on Daple-V2 alone] and Fig. 7A.
www.nature.com/scientificreports/
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early stages in the peripheral blood (most likely from CMCs), suggests that non-canonical Wnt signals are likely 
enhanced and canonical Wnt signals are suppressed early during melanoma progression, a signature that has been 
previously described as a contributor to metastatic features of melanoma and poor survival15–17,32. A decrease 
in the tumor suppressive isoform, Daple-V2 at late stages suggests that canonical Wnt signals are upregulated 
and may be necessary for the growth of metastatic lesions at distant sites. Overall, an increase in Daple-V1 and 
a decrease in Daple-V2 expression correlated with disease progression and emerged from this work as the most 
effective signature in predicting the risk for metastatic progression. Although, this study did not shed light into 
if and how tumor microenvironment may dictate the relative levels of these two transcripts during melanoma 
progression, what is intriguing that this signature also appears to have an overall permissive signaling program in 
colon cancer cells, aiding both tumor cell proliferation (due to low Daple-V2) and EMT (due to high Daple-V1)22.
It is noteworthy that although lower Daple-V2 transcripts in the peripheral circulation were seen predominantly 
in patients with late stage disease, lower Daple-V2 transcripts in the early stage of the disease emerged as the strong-
est predictive profile in our study. This came as an unusual surprise to us because typically biomarkers representative 
of CTCs are elevated in circulation over background, not decreased. These findings raise the possibility that circu-
lating melanocytes may be present in the peripheral circulation of healthy controls, and hence, Daple-V2 transcript 
is detected in the circulation of normal healthy individuals. However, during metastatic progression of melanoma, 
different populations of CMCs that have low Daple-V2 may be disseminated. In fact, this possibility is supported 
by prior studies that reported that melanocyte precursor cells – cells which express TYR and MITF transcripts, 
but not MLANA (or MIF) - may indeed circulate in healthy adults with benign nevus, are detected in human cord 
blood33–35, and during melanocytic differentiation into vein-like structures from pluripotent stem cells36. In patients 
with melanoma, a shift is noted in the landscape of the melanoma transcriptome, i.e., MLANA and MIF transcripts 
are elevated (but not TYR or MITF)34, leading some to speculate that the circulation of normal melanocytic pre-
cursors is inhibited in patients with melanomas, perhaps due to factors, e.g., cytokines released into the systemic 
circulation34. Based on these studies, and our own findings, we conclude that the entry of normal melanocytes and/
or its precursors that have high Daple-V2 is inhibited in patients with melanoma, and instead, melanoma cells with 
lower Daple-V2 begin to enter the circulation. Because the burden of metastatic CMCs in the circulation increases 
with increasing clinical stage of disease5, the prognostic value of decreased Daple-V2 transcript that we observe in 
the early stage suggests that it may be a sensitive method to detect the changing landscape of melanocyte transcripts 
and serve as a surrogate marker for the overall load of metastatic CMCs.
Overall, we conclude that the abundance of Daple transcripts (V1 and V2) in the peripheral blood of patients 
with melanoma may serve as a clinically useful early prognostic test for detecting CMCs in the circulation. 
Because malignant melanoma is a disease that can be characterized by prolonged periods of tumor dormancy, 
which necessitates prolonged periods of follow-up, monitoring Daple transcripts in the peripheral circulation 
may serve as a relatively simple minimally-invasive test, either administered stand-alone, or in combination with 
other panels of melanoma markers. Further studies in larger cohorts are necessary before one can rigorously 
assess and realize the clinical usefulness of Daple in melanoma surveillance during follow-up, to detect tumor 
progression, to monitor response to therapy, and therefore to guide treatment plans.
Materials and Methods
Patient cohort. All samples used in this study were previously analyzed as part of a prior study7, the details 
of which have been well documented. All research was performed in accordance with relevant guidelines/regu-
lations imposed by the IRB. Written informed consent was obtained from 205 patients with primary cutaneous 
melanoma and 142 healthy control participants for this study7. Of the 205, 145 had American Joint Committee on 
Covariate p-value
Hazard 
Ratio [HR]
95% confidence 
interval [CI]
Low Daple-V2 0.0366 8.8907 1.1462 to 68.9638
Age 0.0773 0.9654 0.9283 to 1.0039
Stage 0.0027 4.3313 1.6647 to 11.2692
High Daple-V1 0.1563 2.1933 0.7404 to 6.4973
Age 0.1007 0.971 0.9376 to 1.0057
Stage 0.0028 4.0887 1.6221 to 10.3061
Low Daple-V2 + High Daple-V1 0.0468 8.4 1.0303 to 68.4825
Age 0.6672 0.99 0.9456 to 1.0364
Stage 0.0801 3.247 0.8685 to 12.1400
Table 3. Multivariate analysis.
Transcript name Cut-off valuefor high/low level
Daple-V2 0.7393585
Daple-V1 1.267289
S100A4 1.7226087
Table 4. Cut-off values used for various transcripts.
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Cancers (AJCC) clinical stages 0, I or II (i.e., early stage) and 60 patients had AJCC stages III or IV (i.e., late stage). 
The majority of these patients had no adjuvant therapy (19 patients, 51%). The remaining patients received either 
a combination of post-operative radiation and Dacarbazine (DTIC) treatment (4 patients, 11%), only post-oper-
ative radiation (10 patients, 27%), a combination of post-operative radiation and a melanoma vaccine (1 patient, 
2.75%), a trial BRAF inhibitor (1 patient, 2.75%), Interferon alpha 2b and limb infusion (1 patient, 2.75%) or 
a combination of DTIC, PI-88 and ticilimumab (1 patient, 2.75%). The Human Research Ethics Committees 
of Edith Cowan University (No. 2932) and Sir Charles Gairdner Hospital (No. 2007-123) approved the study. 
Patients were recruited from the Medical Oncology Department of Sir Charles Gairdner Hospital and the Perth 
Melanoma Clinic at Hollywood Hospital (Perth, Western Australia), while the aged-matched, healthy group was 
recruited from the general population. Detailed patient cohort information is listed in Table 1.
Sample collection. As reported previously7, 2.5 ml of whole blood was collected into a PAXgene Blood 
RNA Tube (PreAnalytiX, Hombrechtikon, Switzerland) containing RNA stabilizers. Total RNA was isolated 
using the PAXgene Blood RNA Kit (Qiagen, Hilden, Germany) and then reverse transcription was performed by 
Omniscript Reverse Transcriptase (Qiagen). Clinical data and post-blood collection follow-up was collected for 
all patients over 3 years and 9 months.
As for the timing of sample collection, for the Stage 0, Stage I and Stage II patients underwent venipuncture 
after their curative intent surgery, i.e., after their primary lesion was removed or following a wider excision of 
their primary lesion. Briefly, 43.6% of Stage 0 patients (N = 17) were sampled after a wider excision and 56.4% 
(N = 22) after their primary lesion was removed. Patients were sampled on average 33.5 months after the removal 
of their primary lesion (range 0–168 months) or on average 18.76 months after their wider excision (range 0–56 
months). Among Stage I patients, 35% (N = 28) had blood collected after a wider excision and 65% (N = 52) after 
their primary lesion was removed. Patients were sampled on average 47 months after the removal of their primary 
lesion (range 0–310 months) or on average 44.86 months after their wider excision (range 0–225 months). Among 
Stage II patients, venipuncture occurred after a wider excision for 52.5% (N = 21) of Stage II patients, with the 
remaining 47.5% (N = 19) of Stage II patients sampled after their primary was removed. Patients were sampled on 
average 84 months after the removal of their primary lesion (range 0–1239 months) or an average of 27.76 months 
after their wider excision (range 0–160 months).
As for Stage III patients, they were sampled after the removal of their lymphatic lesions; however, some 
patients went on to develop metastatic lesions in other organs (stage IV) or further lymphatic lesions. Patients 
were sampled on average 12.96 months after the removal of their lymphatic lesion/s (range 0–52 months). Finally, 
for Stage IV patients, 43.2% (N = 16) of them had already undergone surgery for metastatic disease when their 
blood was collected. Patients were sampled on an average of 9.9 months after their surgery (range 0–64 months). 
The remaining 56.8% (N = 21) of Stage IV patients had active disease at the time of blood collection with unre-
moved metastases present.
Melanoma cell lines, RNA isolation, standard curve and quantitative PCR (qPCR). Human mel-
anoma cell line A375 (obtained from ATCC) was grown in Dubecco’s modified Eagle’s medium (DMEM; Gibco) 
media containing 10% fetal bovine serum (Hyclone) in T75 cm2 flask (Corning) until cells were ~70% confluent. 
Cells were then collected and total RNA was isolated using an RNeasy kit (QIAGEN) as per the manufacturers’ 
protocol. First-strand cDNA was synthesized using Superscript II reverse transcriptase (Invitrogen), followed 
by ribonuclease H treatment (Invitrogen) prior to performing quantitative real-time PCR. A standard curve, 
to quantify mRNA copy number, was constructed using larger PCR products (~500 bp) that included the target 
sequence used in qPCR. Reactions omitting reverse transcriptase were performed in each experiment as negative 
controls. Reactions were then run on a real-time PCR system (ABI StepOnePlus; Applied Biosystems). Gene 
expression of Daple-V1, Daple-V2 and S100A4 were detected with Taqman assay (Invitrogen), and relative gene 
expression was determined by normalizing to GAPDH using Relative standard curve method. Primer and probe 
sequences are as listed in Supplementary Table 1 (Table S1).
Analysis of melanoma-associated markers. These analyses were carried out as described previously7. 
Briefly, total RNA (250 ng) was converted to cDNA (Omniscript Reverse Transcriptase, Qiagen), and included 
as a no template control. qRT-PCR assay assessed the number of mRNA transcripts (level of expression) for three 
genes that have been previously shown to be associated with melanoma cells, and in some cases, indicative of 
stemness, i.e., MLANA, ABCB5 and MCAM. GAPDH was assessed as an internal loading control because its level 
is not upregulated in melanoma tissues or cultured cells relative to normal samples37. These assays were carried 
out using SYBR GreenER qPCR SuperMix (Invitrogen) and 200 nmol L−1 of primer (Table S1) and an iCycler 
iQ5 Real-Time Thermocycler (Bio-Rad, Hercules, CA, U.S.A.) as per the manufacturer’s instructions. To prevent 
contamination, all PCR reactions contained uracil-N-glycosylase to prevent reamplification of carryover PCR 
products, and different steps were performed in separate ultraviolet-treatable areas. Melting point determination 
and gel electrophoresis confirmed the expected size and identity of PCR products. Every assay included a stand-
ard curve, negative controls (no template and reverse transcription control), positive control (A2058 cell line) and 
cDNA from a single healthy control.
Statistical analyses. Statistical evaluation was performed using the GraphPad prism v5 software. Statistical 
significance of differences in marker expression among the patients with early vs. late stages of melanoma and 
normal healthy controls was analyzed using unpaired t-test. Optimal cut-off values for gene expression levels were 
derived using the web-based tool-Cutoff Finder (R Software v2.15.038) by maximally selected log-rank statistics. 
We chose the method–‘Significance of correlation with survival variable’ for cutoff optimization over ‘ROC curve 
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analysis’ from Cutoff Finder because this method fits Cox proportional hazard models to dichotomized variables 
and survival variables which is executed using the functions coxph and survfit from the survival package. The 
optimal cutoff is defined as the point with the most significant (log-rank test) split. The relationship between 
high vs. low levels of gene expression and incidence of metastatic progression was investigated by Fisher’s exact 
test. The association between melanoma stage and expression level of Daple-V1/V2 and S100A4 was carried out 
by Chi-square test for trend. Cox proportional hazard regression analysis was used to generate hazard ratio and 
confidence interval of transcrips. To assess the relationship between gene expression and patient’s age, clinical 
stage of disease, Clark level, Breslow thickness and ulceration, we usedparametric Pearson’s correlation and non-
parametric Spearman’s correlation analyses. To estimate the correlation among the expression levels of various 
genes tested here, we used Correlation Matrix. To analyze the effect of high vs. low levels of gene expression and 
time-dependent survival probabilities we used Kaplan-Meier (KM)analyses. All statistical tests were performed 
two-sided, and p- values less than 0.05 were considered as statistically significant.
Data Availability Statement
All data generated or analyzed during this study are included in this published article (and its Supplementary 
Information Files). The raw datasets generated during and/or analyzed during the current study are available 
from the corresponding author on reasonable request. The TCGA datasets analyzed during the current study are 
available in the cBioPortal repository, [http://www.cbioportal.org/].
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